Among them, CT8+T cells, the immune cell with the most prominent tumor killing ability (63, 64), were significantly reduced in S100A2 high expression group, which partially explained the poor prognosis of patients with high S100A2 expression. This evidence concerns the gene S100A2 and neoplasm.